Legend Biotech highlights new CARVYKTI data in RRMM

Legend Biotech (LEGN) announced new long-term clinical and translational data for CARVYKTI from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed / refractory multiple myeloma, RRMM, patients. In triple-class-exposed patients who had received three prior lines of therapy, a median progression-free survival, mPFS, of 50.4 months was observed following a single infusion of CARVYKTI. These results, presented in an oral presentation at the 67th American Society of Hematology, ASH, Annual Meeting, add to a body of clinical evidence and real world experience supporting the long-term benefits of CARVYKTI, which has treated over 9,000 patients globally. Building on these outcomes, findings from CARTITUDE-1 and CARTITUDE-4 demonstrated that patients treated earlier, after one or two prior lines of therapy, exhibited stronger immune fitness. These patients had higher baseline levels of CD4+ naive T cells and a more immunocompetent tumor microenvironment, biological features that suggest an association with longer PFS and consistent with the observation that mPFS had not been reached in as-treated CARTITUDE-4 patients at a median follow-up of 34 months.